Research Output per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
Mantle-Cell Lymphoma
Medicine & Life Sciences
Hodgkin Disease
Medicine & Life Sciences
Radiotherapy
Medicine & Life Sciences
Acute Myeloid Leukemia
Medicine & Life Sciences
Peripheral T-Cell Lymphoma
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Cyclophosphamide
Medicine & Life Sciences
Lymphoma, Large B-Cell, Diffuse
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2006 2019
ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study
Strati, P., Fanale, M. A., Oki, Y., Turturro, F., Fayad, L. E., Bartlett, N. L., Gladstone, D. E., Kasamon, Y. L., Portlock, C. S., Wilson, W. H., Goy, A., Younes, A. & Lee, H. J., Feb 1 2019, In : Haematologica. 104, 2, p. e65-e67Research output: Contribution to journal › Letter
A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma
Lee, H. J., Badillo, M., Romaguera, J. & Wang, L., Feb 1 2019, In : British Journal of Haematology. 184, 3, p. 460-462 3 p.Research output: Contribution to journal › Letter
Mantle-Cell Lymphoma
carfilzomib
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy
Yoder, A. K., Gunther, J., Milgrom, S. A., Mirkovic, D., Nastoupil, L., Neelapu, S. S., Fanale, M. A., Fowler, N., Westin, J. R., Lee, H. J., Rodriguez, M. A., Iyer, S. P., Fayad, L. E., Nieto, Y., Hosing, C., Ahmed, S., Medeiros, L. J., Khoury, J., Garg, N., Amini, B. & 2 others, Jan 1 2019, In : Clinical Lymphoma, Myeloma and Leukemia. 19, 1, p. e51-e61Research output: Contribution to journal › Article
Mesentery
Lymphoma, Large B-Cell, Diffuse
Radiotherapy
Disease-Free Survival
Tomography
1
Citations
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
Jain, P., Romaguera, J., Srour, S., Lee, H. J., Hagemeister, F. B., Westin, J. R., Fayad, L. E., Samaniego, F., Badillo, M., Zhang, L., Nastoupil, L., Kanagal Shamanna, R., Fowler, N. & Wang, L., Aug 1 2018, In : British Journal of Haematology. 182, 3, p. 404-411 8 p.Research output: Contribution to journal › Article
Mantle-Cell Lymphoma
Phase II Clinical Trials
Therapeutics
Survival
Myalgia
Integrated stress response and immune cell infiltration in an ibrutinib-refractory mantle cell lymphoma patient following ONC201 treatment
Romaguera, J. E., Lee, H. J., Tarapore, R., Prabhu, V., Allen, J., Schalop, L., Zloza, A., Ok, C. Y., Sadimin, E. T., Schenkel, J., Badillo, M. & Wang, L., Jan 1 2018, (Accepted/In press) In : British Journal of Haematology.Research output: Contribution to journal › Article
Mantle-Cell Lymphoma
Therapeutics
TIC10 compound
PCI 32765